Copyright
©2010 Baishideng.
World J Gastrointest Oncol. Jun 15, 2010; 2(6): 251-258
Published online Jun 15, 2010. doi: 10.4251/wjgo.v2.i6.251
Published online Jun 15, 2010. doi: 10.4251/wjgo.v2.i6.251
Table 1 Comparison of clinicopathological features of goblet cell carcinoid, carcinoid & adenocarcinoma
| Goblet cell carcinoid | Carcinoid | Adenocarcinoma | |
| Clinical features | |||
| Age | 5th-6th decade | 4th decade | 7th decade |
| Carcinoid syndrome | No | Yes | No |
| Primary symptoms | Acute appendicitis | Acute appendicitis | Mass |
| Gross appearance | > 2 cm, ill defined thickening | < 2 cm | > 2 cm, well defined mass |
| Microscopic appearance | |||
| Morphology | Clusters of goblet or signet-ring cells separated by fibrosis/pools of mucin | Nests of small cells | Well-formed glands to sheets of poorly differentiated signet-ring cells |
| Atypia | Minimal | Minimal | Marked |
| Mitosis | Rare | Rare | Increased |
| Vascular and perineural invasion | Present | Absent | Present |
| Infiltrative margins | Present | Absent | Present |
| Special stains | |||
| Argyrophil | Positive | Positive | Usually negative |
| Argentaffin | Negative | Positive | Negative |
| Mucicarmine/PAS/PASD | Positive in goblet cells | Negative | Positive |
| IHC | |||
| CEA | + | - | + |
| CDX2 | + | - | + |
| CAM5.2 | + | - | + |
| CK20 | ± | - | + |
| CK7 | ± | - | - |
| CK19 | + | - | - |
| Neuroendocrine markers | ± | ± | - |
| Math1 and HD5 | + | - | + |
| p53, p16 | - | - | + |
| Molecular pathology | |||
| DPC4, Kras, β-catenin mutation and p53 over expression | - | - | + |
Table 2 Treatment guidelines recommended by various authors (1974-2008)
| Subbuswamy et al[2] | APX |
| RH in case of cecal involvement | |
| Klein[3] | APX |
| Haqqani et al[40] | RH if base of appendix or caecum is involved |
| Warkel et al[4] | RH in case of spread beyond appendix, atypia, and mitotic count ≥ 2/10 hpf |
| Chen et al[41] | APX alone unless there is cecal involvement |
| Olsson et al[42] | RH in case of spread beyond appendix, atypia, and mitotic count ≥ 2/10 hpf |
| Edmonds et al[33] | RH in all cases |
| Bak et al[39] | RH in case of spread beyond appendix, atypia, and mitotic count ≥ 2/10 hpf |
| Park et al[43] | RH in all cases |
| Rutledge et al[44] | RH in all cases |
| Butler et al[36] | RH for cecal involvement, BSO in females |
| Ramnani et al[13] | < 2 cm in size, without serosal & lymphatic involvement-APX |
| More advanced tumor-RH | |
| Kanthan et al[30] | RH |
| Li et al[31] | RH for N1, M1 or Mib1 > 3% |
| Varisco et al[23] | RH in case of spread beyond appendix, atypia, and mitotic count ≥ 2/10 hpf |
| Byrn et al[35] | No value of RH in non-metastatic cases |
| Pham et al[22] | RH with attendant mesenteric nodal resection for (1) T3/T4 disease or nodal involvement; (2) direct cecal involvement; and (3) clinically positive mesenteric nodes |
| Bilateral oophorectomy for post menopausal women | |
| O’Donnell et al[20] | RH irrespective of stage |
| Tang et al[17] | Group A T1, 2-no recommendations |
| T3 or 4, group B/C, perforation, positive margin-RH with oophorectomy if possible. CT in stage III/IV | |
| Stage IV/group C- debulking/oophorectomy/systemic/intraperitoneal CT |
- Citation: Roy P, Chetty R. Goblet cell carcinoid tumors of the appendix: An overview. World J Gastrointest Oncol 2010; 2(6): 251-258
- URL: https://www.wjgnet.com/1948-5204/full/v2/i6/251.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v2.i6.251
